Roche comes up short in its at­tempt to hold off gener­ic com­pe­ti­tion to Es­bri­et

Roche’s block­buster id­io­path­ic pul­monary fi­bro­sis drug Es­bri­et brings in more than $1 bil­lion a year — and the Swiss phar­ma gi­ant would like to keep it that way. Too bad a Delaware fed­er­al judge doesn’t agree.

US Dis­trict Judge Richard An­drews ruled on Tues­day that No­var­tis’ San­doz unit didn’t in­fringe on Roche’s patents with its sub­mis­sion of ab­bre­vi­at­ed NDAs (AN­DAs) for its pir­fenidone gener­ic tablets, and found that some of those patent claims are in­valid due to “ob­vi­ous­ness.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.